About AROG Pharmaceuticals

Arog Pharmaceuticals is a Phase 3 biopharmaceutical company dedicated to developing our lead investigational drug candidate, crenolanib, and a related class of benzimidazole-based compounds to become treatment options for cancer indications with high unmet medical need.

We founded Arog in 2010 after securing exclusive global rights to our product candidates from Pfizer. Since then, we have enrolled hundreds of patients in completed or ongoing clinical trials in acute myelogenous leukemia (AML) and advanced solid tumors.

Indication Patient subset Phase I Phase II Phase III
FLT3 Pipeline
AML Relapsed/Refractory (2L & 3L) NCT03250338
Newly Diagnosed (1L) NCT03258931
Post-Transplant maintenance NCT02400255
Solid Tumor Pipeline
GIST PDGFRa D842V mutated NCT02847429
Glioma PDGFRa  amplification NCT02626364
Gastric Relapsed/Refractory NCT03193918

Patient Focused Clinical Trial Design

We are currently enrolling multiple global Phase 3 studies designed, if successful, to position crenolanib as a targeted treatment option in combination with intensive chemotherapy for newly diagnosed and relapsed or refractory FLT3 AML and as monotherapy treatment for advanced or metastatic gastrointestinal stromal tumors (GIST) with a D842V mutation.

We are also enrolling clinical studies for advanced second-line gastric cancer in combination with ramucirumab and paclitaxel and as a monotherapy for recurrent or refractory glioblastoma.

View Our Programs





Ready to Learn More?

Contact us today and find out how we can help

Contact Us